Navigation Links
OncoSec Medical Announces $7.2 Million Public Offering
Date:12/13/2012

SEC's website at www.sec.gov or by request at Dawson James Securities, Inc. by e-mailing placements@djsiny.com.

This announcement is neither an offer to sell nor a solicitation of an offer to buy any of OncoSec's common stock or warrants. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

About OncoSec Medical Inc.

OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives.  OncoSec Medical's core technology is based upon its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at http://www.oncosec.com/.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's cu
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. OncoSec Medical Issues Letter to Shareholders
3. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
4. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
5. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
6. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
7. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
8. OncoSec Granted New Patent from China
9. OncoSec to Present at Upcoming Healthcare and Investor Conferences
10. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
11. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013  Lakeland Industries, Inc. (NASDAQ: LAKE ... industry, healthcare and to first responders on the federal, ... for the fiscal 2013 fourth quarter and year ended ... stock market close and will conduct a conference call ... (Logo: http://photos.prnewswire.com/prnh/20120611/NY21959LOGO ) The ...
(Date:5/17/2013)... DIEGO and CAMBRIDGE, Mass., May 17, 2013 /PRNewswire/ ... that a purchaser of Aveo Pharmaceutical, Inc. (NASDAQGS: AVEO) ... Court for the District of Massachusetts ... its officers violated the Securities Exchange Act of 1934 ... 1, 2013 (the "Class Period"). (Logo: ...
(Date:5/17/2013)... PHILADELPHIA , May 17, 2013 ... disorders; health economics and outcomes research also   to ... SHP, NASDAQ: SHPG ), the global specialty ... in 7 poster presentations at the American Psychiatric Association ... , May 18-22. The data being presented represent ...
Breaking Medicine Technology:Lakeland Industries to Report Fiscal Fourth Quarter and Year End Financial Results and Conduct Conference Call 2Aveo Pharmaceuticals, Inc. Sued by Investor 2Aveo Pharmaceuticals, Inc. Sued by Investor 3Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 2Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 3Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 4Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 5Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 6Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 7Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 8Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 9Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 10
... 3, 2012 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP ... biotechnology research and development outsourcing company, today announced that it ... ended March 31, 2012 on May 17, 2012. Management will ... New York Time on May 17, 2012 (8:00PM Beijing Time ...
... Pharmaceuticals, Inc. (NASDAQ: OPTR ) today announced ... America Merrill Lynch 2012 Health Care Conference on Thursday, May 17 ... (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ) A ... on the Investors page of the Company,s website at ...
Cached Medicine Technology:ShangPharma to Report First Quarter 2012 Financial Results on May 17, 2012 2
(Date:5/19/2013)... 2013 Actos lawsuit claims ... underway in U.S. District Court, Western District of Louisiana. ... 3rd, the Court has modified the litigation’s Bellwether Nomination ... rather than four. The next Status Conference in the ... (In re: Actos Product Liability Litigation, MDL No. 2299) ...
(Date:5/19/2013)... Grinding your teeth at night can ... annoying your spouse. At the same time, according to ... and Teeth Grinding Could Be a Sign of Sleep ... be hard to prevent. Apparently, Obstructive Sleep Disorder (OSD) ... its symptoms is a habit of teeth grinding along ...
(Date:5/19/2013)... 2013 These molecular diagnostics market ... Spain, Japan, Italy, Germany and France:, ... laboratory practice, as well as key economic, regulatory, ... impact during the next five years. , ... technologies, test formats, detection methodologies, trends in testing ...
(Date:5/19/2013)... York (PRWEB) May 19, 2013 The ... Case Management Conference was recently convened for hundreds of ... multidistrict litigation now underway in U.S. District Court, Southern ... the Court’s website on May 14th, the Conference addressed ... was also reported during the Conference that Defendants submitted ...
(Date:5/19/2013)... Keith Chertok now provides gum disease patients with a new ... chance of a healthier smile. Laser gum surgery ... removes diseased gum tissue in patients, but it also stimulates ... implants. , LANAP uses a laser to successfully treat ... the healthy tissue as well as encourage new bone growth. ...
Breaking Medicine News(10 mins):Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Dr. Kanani, Woodland Hills Dentist: Dangers of Tooth Damage and Obstructive Sleep Disorder 2Health News:Dr. Kanani, Woodland Hills Dentist: Dangers of Tooth Damage and Obstructive Sleep Disorder 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 4Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 2Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 3Health News:Berkeley, CA Periodontist, Dr. Keith Chertok Now Treats Gum Disease Patients With Laser Gum Surgery Prior to Placing Dental Implants 2
... Medical, Inc., a,privately held medical device company and ... announce the addition of two officers to,their management ... Finance and Chief Financial Officer. Tara Zerby joins ... "We are very excited to have Malcolm ...
... (NASDAQ: QLTI;,TSX: QLT) today announced that following a months-long business ... several,new initiatives designed to enhance shareholder value., These ... USA, Inc. whose primary assets include the Eligard(R) ... dermatology product for the treatment ...
... JOLLA, Calif., Jan. 16 Immunosyn,Corporation (OTC Bulletin ... of an Equity Research Profile on the company ... research company, nor the,associated press release announced earlier ... only authorized public and investor,relations firm retained by ...
... 17 One of Australia,s largest,pharmacy groups, Chemmart, has ... competitive threat posed by discount chains., The system ... month of,operation, participating pharmacies signed up more than 30,000 ... Results Group, has now been,rolled out to more than ...
... interventions were implemented in poor countries, cases of stunting among ... by up to a quarter, according to new research being ... of Hygiene & Tropical Medicine, is one of the authors ... Maternal and Child Undernutrition Series, which is being launched this ...
... MOUND, Texas, Jan. 16 American,HealthChoice, Inc. (Pink Sheets: ... and Tennessee, today, in an update for Company,shareholders, said ... 2007,totaled $243,000., "It was a year of positioning, ... CEO. "I am updating our shareholders on these,achievements as ...
Cached Medicine News:Health News:Cardiva Medical, Inc. Appoints Two New Officers: Malcolm Farnsworth as Vice President of Finance and Chief Financial Officer and Tara Zerby as Vice President of Business Development and Marketing 2Health News:QLT Inc. announces initial steps in strategic restructuring 2Health News:QLT Inc. announces initial steps in strategic restructuring 3Health News:QLT Inc. announces initial steps in strategic restructuring 4Health News:Equity Research Firm Issued Unauthorized Report and Press Release on Immunosyn Corporation Today 2Health News:Chemmart(R) Sees Instant Results From Launch of New Rewards Program 2Health News:One third of stunting and a quarter of deaths among under 3s in poor countries could be prevented 2Health News:American HealthChoice CEO Dr. J.W. Stucki Provides Company Update 2Health News:American HealthChoice CEO Dr. J.W. Stucki Provides Company Update 3
... Used retrograde to ... establish a Peel-Away ureteral ... The temporary protective Peel-Away ... away as the ureteroscope ...
The removable inflation/injection adapter allows the cystoscope to be removed after the catheter is in place. Supplied sterile in peel-open packages. Intended for one-time use....
Radiopaque markers are placed at the proximal and distal ends of the balloon. A special pin vise handle is included to stabilize the wire guide during introduction. Supplied sterile in peel-open pack...
Used during the performance of balloon dilation procedures to inflate and deflate the balloon and measure the pressure within the balloon during the procedure. Supplied sterile in peel-open packages....
Medicine Products: